Beta-Galactosidase Fragment Plasmid for Antibiotic-Free Gene Therapy Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current plasmid vectors for gene therapy and biologic manufacturing often rely on antibiotic resistance markers, which are undesirable due to regulatory concerns and can cause gene silencing, necessitating the development of smaller plasmids with alternative selectable markers.
Innovation Solution
The use of β-galactosidase expression cassettes with an amino-terminal fragment linked to a promoter, combined with a high-copy replication origin and dimer resolution element, to create smaller plasmids that can be selectively maintained in host cells without antibiotic resistance genes, allowing for efficient plasmid-based gene therapy applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotic resistance genes are used as selectable markers, then selection of plasmid-containing cells is achieved, but regulatory concerns and gene silencing issues arise
Solution Approach 1:
The patent extracts and removes the antibiotic resistance gene from the plasmid vector, replacing it with a non-antibiotic selectable marker system. Specifically, the invention uses a metabolic selection system where the plasmid encodes enzymes (such as thymidine kinase or other metabolic pathway enzymes) that enable host cells to utilize specific carbon sources or amino acids, thereby achieving selection without antibiotic resistance genes.
Solution Approach 2:
The patent changes the selection mechanism from antibiotic-based to metabolism-based selection. By altering the selectable marker type from antibiotic resistance to metabolic capability, the system achieves the same selection function while eliminating the harmful effects of antibiotic resistance genes.
2Quantity of substance
If large plasmids are used for gene therapy, then sufficient expression capacity is achieved, but transfection efficiency and production costs increase
Solution Approach 1:
The patent segments the plasmid structure into essential and non-essential components, removing unnecessary elements such as antibiotic resistance genes, extensive multiple cloning sites, and redundant regulatory sequences. This segmentation allows retention of only the critical elements needed for expression (promoter, gene of interest, terminator, origin of replication, and non-antibiotic selectable marker), thereby reducing overall plasmid size while maintaining expression capacity.
Solution Approach 2:
The patent extracts and removes bloat elements from the plasmid vector including large antibiotic resistance gene cassettes, extensive multiple cloning sites, and redundant regulatory sequences, leaving only the minimal necessary components for functional expression and selection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables stable plasmid maintenance and expression in host cells, reducing the risk of gene silencing and regulatory issues, while facilitating the use of smaller plasmids for therapeutic applications, including transient transfection and clinical material production.
Implementation Method 1
The nucleic acid construct comprises an isolated β-galactosidase expression cassette comprising a nucleic acid sequence encoding the amino-terminal fragment of β-galactosidase operably linked to a promoter
Data Source
AI summary
Provided herein are methods of using a nucleic acid construct as a selectable marker. The nucleic acid construct comprises an isolated β-galactosidase expression cassette comprising a nucleic acid sequence encoding the amino-terminal fragment of β-galactosidase operably linked to a promoter. Also provided are isolated vectors comprising the β-galactosidase expression cassette, methods of generating the isolated vector, and kits comprising the isolated vector.